Sofosbuvir

Summarized by Plex Health
Last Updated: 03 May 2022

Sofosbuvir is an antiviral medication that is used to deal with chronic hepatitis C in adults and children that go to at least 3 years of ages. Sofosbuvir is often used in people that also have HIV, or people who have liver cancer and are most likely to have a liver transplant. It may become active or get even worse while using or after you quit utilizing sofosbuvir if you've ever before had hepatitis B. Check out the medication guide or patient directions given with each medication in your combination therapy. When amiodarone was given with sofosbuvir and specific other liver disease C drugs, sluggish heart beat and the requirement to get a pacemaker have taken place. Sluggish heart beat has happened up to 2 weeks after starting liver disease C treatment. When taking sofosbuvir with other medicine: To ensure all medicines are secure for you, tell your medical professional about all your clinical conditions, and if you are pregnant or breastfeeding. Both men and women utilizing ribavirin needs to use effective contraception to protect against maternity. If a maternity takes place while either the papa or the mom is using ribavirin, inform your medical professional right away. Your child's dose requirements may change if the child gains or slims down. This virus may come to be active or get even worse while you are making use of sofosbuvir or in the months after you stop if you've ever before had hepatitis B. You might require liver function tests for numerous months after your last dose. Quiting suddenly can make your hepatitis C tougher to treat with antiviral medication. Every person with chronic liver disease C need to remain under the care of a medical professional. 400 mg by mouth daily Recommended Regimen and Duration of Therapy: -Genotype 1 or 4: Sofosbuvir, peginterferon alfa, and ribavirin for 12 weeks -Genotype 2: Sofosbuvir and ribavirin for 12 weeks -Genotype 3: Sofosbuvir and ribavirin for 24 weeks -Hepatocellular carcinoma awaiting liver transplantation: Sofosbuvir and ribavirin for as much as 48 weeks or till liver transplantation Comments: -Genotype 1, 4: This regimen is advised for therapy-naive patients without cirrhosis or with compensated cirrhosis -The maker item information must be gotten in touch with for ribavirin tablet dosage suggestions; with genotype 1 or 4, the manufacturer item information for peginterferon alfa need to additionally be consulted for dose recommendations. -Sofosbuvir and ribavirin for 24 weeks can be considered for patients with genotype 1 infection that can not use an interferon-based program; therapy decision must be assisted by benefit/risk evaluation for the specific patient. -The regimen for patients with hepatocellular carcinoma waiting for liver transplantation is suggested to stop posttransplant HCV reinfection. -The routine for patients with hepatocellular cancer waiting for liver transplantation is advised to stop posttransplant HCV reinfection. Use: In combination with ribavirin, for the treatment of chronic HCV genotype 2 or 3 infection in patients without cirrhosis or with compensated cirrhosis.

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

** If you believe that content on the Plex is summarised improperly, please, contact us, and we will get rid of it quickly; please, send an email with a brief explanation.

PubChem - CovalentUnitCount

(Table source)
CIDMolecularFormulaMolecularWeightCanonicalSMILESIsomericSMILESInChIInChIKeyIUPACNameXLogPExactMassMonoisotopicMassTPSAComplexityChargeHBondDonorCountHBondAcceptorCountRotatableBondCountHeavyAtomCountIsotopeAtomCountAtomStereoCountDefinedAtomStereoCountUndefinedAtomStereoCountBondStereoCountDefinedBondStereoCountUndefinedBondStereoCountCovalentUnitCount
45375808C22H29FN3O9P529.5CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3C[[email protected]@H](C(=O)OC(C)C)N[[email protected]](=O)(OC[[email protected]@H]1[[email protected]]([[email protected]@]([[email protected]@H](O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1TTZHDVOVKQGIBA-IQWMDFIBSA-Npropan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate1529.16254467529.162544671539130311113606600001
*** If you want us to remove all links leading to your domain from Plex.page and never use your website as a source of the "Online Knowledge", please contact us using a corporate email and we will remove everything in 10 business days.

logo

Plex Page is a Biology & Health Sciences "Online Knowledge Base," where a machine summarizes all the summaries.